📊 EVFM Key Takeaways
Is Evofem Biosciences, Inc. (EVFM) a Good Investment?
Evofem Biosciences exhibits severe financial distress with negative stockholders' equity of -$74.3M, indicating the company is technically insolvent. Despite modest revenue growth of 4.2% YoY and a 16.7% operating margin, negative operating cash flow of -$2.0M and critically low liquidity (0.18x current ratio) with only $578K in cash create an imminent solvency crisis. The company's ability to continue operations is highly questionable without immediate capital restructuring or substantial external financing.
Evofem Biosciences shows a modest improvement in revenue and reported net income, but the quality of earnings appears weak because operating cash flow and free cash flow remain negative. The balance sheet is severely impaired, with negative equity, very low cash, and acute liquidity stress, which outweighs the recent profitability improvement.
Why Buy Evofem Biosciences, Inc. Stock? EVFM Key Strengths
- Positive net income of $391K with 42.7% YoY improvement showing path to profitability
- Modest revenue growth of 4.2% YoY indicating stable top-line performance
- Relatively strong operating margin of 16.7% demonstrating operational efficiency
- Revenue grew 4.2% year over year, indicating some top-line stability
- Operating income was positive at $3.37M, with a 16.7% operating margin
- Net income improved 42.7% year over year, showing better reported profitability
EVFM Stock Risks: Evofem Biosciences, Inc. Investment Risks
- Negative stockholders' equity of -$74.3M indicating technical insolvency and balance sheet distress
- Critical liquidity crisis with current ratio of 0.18x and only $578K cash against $89.7M total liabilities
- Severely negative operating cash flow of -$2.0M suggesting the company is burning cash and cannot sustain operations without external funding
- Negative free cash flow of -$2.0M with -9.9% FCF margin indicating unsustainable business model
- High leverage with $2.8M long-term debt and weak interest coverage of 1.4x
- Zero insider Form 4 filings in last 90 days indicating lack of insider confidence
- Current ratio of 0.18x and cash of only $578K indicate severe near-term liquidity risk
- Negative stockholders equity of $-74.34M reflects a deeply impaired balance sheet
- Operating cash flow of -$1.99M shows earnings are not converting into cash
Key Metrics to Watch
- Operating cash flow trajectory and path to positive free cash flow
- Cash balance and runway given current burn rate
- Stockholders' equity recovery and balance sheet restructuring efforts
- Revenue growth acceleration beyond 4.2% to support profitability scaling
- Quarterly operating cash flow and free cash flow trend
- Cash balance and current liabilities coverage
Evofem Biosciences, Inc. (EVFM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
EVFM Profit Margin, ROE & Profitability Analysis
EVFM vs Healthcare Sector: How Evofem Biosciences, Inc. Compares
How Evofem Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Evofem Biosciences, Inc. Stock Overvalued? EVFM Valuation Analysis 2026
Based on fundamental analysis, Evofem Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Evofem Biosciences, Inc. Balance Sheet: EVFM Debt, Cash & Liquidity
EVFM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Evofem Biosciences, Inc.'s revenue has grown significantly by 11% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.11 indicates the company is currently unprofitable.
EVFM Revenue Growth, EPS Growth & YoY Performance
EVFM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $4.5M | $956.0K | $-0.01 |
| Q2 2025 | $4.2M | -$828.0K | $0.00 |
| Q1 2025 | $845.0K | $956.0K | $0.00 |
| Q3 2024 | $4.5M | $1.4M | $-0.02 |
| Q2 2024 | $2.5M | $1.4M | $0.00 |
| Q1 2024 | $3.6M | -$2.4M | $-0.16 |
| Q3 2023 | $5.1M | -$2.4M | $0.09 |
| Q2 2023 | $2.5M | -$2.4M | $-5.43 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Evofem Biosciences, Inc. Dividends, Buybacks & Capital Allocation
EVFM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Evofem Biosciences, Inc. (CIK: 0001618835)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EVFM
What is the AI rating for EVFM?
Evofem Biosciences, Inc. (EVFM) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 93% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EVFM's key strengths?
Claude: Positive net income of $391K with 42.7% YoY improvement showing path to profitability. Modest revenue growth of 4.2% YoY indicating stable top-line performance. ChatGPT: Revenue grew 4.2% year over year, indicating some top-line stability. Operating income was positive at $3.37M, with a 16.7% operating margin.
What are the risks of investing in EVFM?
Claude: Negative stockholders' equity of -$74.3M indicating technical insolvency and balance sheet distress. Critical liquidity crisis with current ratio of 0.18x and only $578K cash against $89.7M total liabilities. ChatGPT: Current ratio of 0.18x and cash of only $578K indicate severe near-term liquidity risk. Negative stockholders equity of $-74.34M reflects a deeply impaired balance sheet.
What is EVFM's revenue and growth?
Evofem Biosciences, Inc. reported revenue of $20.2M.
Does EVFM pay dividends?
Evofem Biosciences, Inc. pays dividends, with $0.2M distributed to shareholders in the trailing twelve months.
Where can I find EVFM SEC filings?
Official SEC filings for Evofem Biosciences, Inc. (CIK: 0001618835) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EVFM's EPS?
Evofem Biosciences, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EVFM a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Evofem Biosciences, Inc. has a STRONG SELL rating with 93% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EVFM stock overvalued or undervalued?
Valuation metrics for EVFM: ROE of N/A (sector avg: 15%), net margin of 1.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EVFM stock in 2026?
Our dual AI analysis gives Evofem Biosciences, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EVFM's free cash flow?
Evofem Biosciences, Inc.'s operating cash flow is $-2.0M, with capital expenditures of $5.0K. FCF margin is -9.9%.
How does EVFM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 1.9% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.18 (avg: 2).